Impact of coronavirus disease pandemic on antimicrobials consumption and antimicrobial resistance during the first and second wave in a tertiary care hospital, in India
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20233194Keywords:
COVID-19, Define daily dose, AWaRe classification, Hospital-acquired bloodstream infections, Antimicrobial resistanceAbstract
Background: This study measured the impact of the first and second wave of COVID-19 pandemic (in the year 2020-21) on the antibiotics uses and their effect on gram nehative bacterial species Klebsiella, Enterobacter, Pseudomonas and Acinetobacter.
Methods: The number of patient admission month-wise, antibiotic consumption, blood cultures collected, number of positive BCs, and antibiotic resistance were analysed retrospectively for the years 2020, 2021, and 2019 for comparison, in tertiary care hospital (ca. 840 beds).
Results: Half of patients admitted in years 2020 and 2021 in our hospital had COVID-19. A significant increase in total antibiotic consumption during the years 2020 (75.53 DDD per 100 admissions) and 2021 (91.71 DDD per 100 admissions) occurred in comparison to the year 2019 (52.5 DDD per 100 admissions). The rate ratio of BCs per 100 admissions increased by 74% in the year 2020, and 118% in the year 2021 in comparison with the rate ratio to the year 2019. The BSI rate per 100 admissions increased overall by 24% in March 2020 and 115% in April 2020, the rate ratio of BSIs per 100 admissions raised 58.4% for Klebsiella and 239.3% for E. coli, but remain the same for Acinetobacter and Aeruginosa. A sharp increase in the rate of BSIs caused by microorganisms resistant to cephalosporins was also observed in the years 2020 and 2021.
Conclusions: present study highlights the impact of the first and second waves of the COVID-19 pandemic on antibiotic consumption and the increasing prevalence hospital-acquired infections and antimicrobial resistance.
Metrics
References
Gorbalenya AE. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020;5: 536-44.
Dryden M, Johnson AP, Ashiru-Oredope D, Sharland M. Using antibiotics responsibly: right drug, right time, right dose, right duration. J Antimicrob Chemother. 2011;66(11):2441-3.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223): 507-13.
Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and Fungal Coinfection among Hospitalized Patients with COVID-19. Clin Microbiol Infect 2020;26(10):1395-9.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.
Sharifipour E, Shams S, Esmkhani M, Khodadadi J, Fotouhi-Ardakani R, Koohpaei A, et al. Evaluation of Bacterial Co-Infections of the Respiratory Tract in COVID-19 Patients Admitted to ICU. BMC Infect Dis. 2020;20(1):646.
COVID-19. Available at: https://www.cdc.gov/drug resistance/covid19.html. Accessed on 22 December 2021.
WHO Collaborating Center for Drug Statistics Methodology. Available at: https://www.who.int. Accessed on 22 December 2021.
Antibiotics. Available at: https://www.who.int/ medicines/news/2019/WHO_releases2019AWaRe_classification_antibiotics/en/. Accessed on 22 December 2021.
Sharland M, Pulcini C, Harbarth S, Zeng M, Gandra S, Mathur S, Magrini N. Classifying antibiotics in the WHO essential medicines list for optimal use be AWaRe. Lancet Infect Dis. 2018;18(1):18-20
Corona virus disease. Available at: https://ncdc. gov.in/showfile.php?lid=324. Accessed on 22 December 2021.
Grau S, Echeverria-Esnal D, Gómez-Zorrilla S, Navarrete-Rouco ME, Masclans JR, Espona M, et al. Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic. Antibiotics. 2021; 10(2):132.
Rawson TM, Ming D, Ahmad R, Moore LSP, Holmes AH. Antimicrobial use, drug-resistant infections and COVID-19. Nat Rev Microbiol. 2020;18(8):409-10.
Hussein RR, Rabie ASI, Bin Shaman M, Shaaban AH, Fahmy AM, Sofy MR, et al. Antibiotic consumption in hospitals during COVID-19 pandemic: a comparative study. J Infect Dev Ctries. 2022;16(11):1679-86.
Ul Mustafa Z, Salman M, Aldeyab M, Kow CS, Hasan SS. Antimicrobial consumption among hospitalized patients with COVID-19 in Pakistan. SN Compr Clin Med. 2021;3(8):1691-5.
Gonzalez-Zorn B. Antibiotic use in the COVID-19 crisis in Spain. Clin Microbiol Infect. 2021;27:646-7.
Aldeyab M, López-Lozano JM, Gould IM. Global Antibiotics Use and Resistance. In: Global Pharmaceutical Policy. Singapore; Palgrave Macmillan: 2020.
Conlon-Bingham GM, Aldeyab M, Scott M, Kearney MP, Farren D, Gilmore F, et al. Effects of Antibiotic Cycling Policy on Incidence of Healthcare-Associated MRSA and Clostridioides difficile Infection in Secondary Healthcare Settings. Emerg Infect Dis. 2019; 25(1):52-62.
Jirjees FJ, Al-Obaidi HJ, Sartaj M. Antibiotic Use and Resistance in Hospitals: Time-Series Analysis Strategy for Determining and Prioritising Interventions. Hosp Pharm Eur. 2020;23:13-9.
Global action plan on antimicrobial resistance. Available at: https://www.who.int. Accessed on 20 February 2021.
Elhajji FD, Al-Taani GM, Anani L, Al-Masri S, Abdalaziz H, Qabba'h SH, et al. Comparative point prevalence survey of antimicrobial consumption between a hospital in Northern Ireland and a hospital in Jordan. BMC Health Serv Res. 2018;18(1):849.
GLASS Guide for National Surveillance Systems for Monitoring Antimicrobial Consumption in Hospitals. Available at: https://www.who.int. Accessed on 20 February 2021.
The 2019 WHO AWaRe Classification of Antibiotics for Evaluation and Monitoring of Use. Available at: https://www.who.int. Accessed on 20 February 2021.
Sharland M, Gandra S, Huttner B, Moja L, Pulcini C, Zeng M, et al. Encouraging AWaRe-ness and discouraging inappropriate antibiotic use-the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. Lancet Infect Dis. 2019;19(12):1278-80.
King LM, Lovegrove MC, Shehab N, Tsay S, Budnitz DS, Geller AI, et al. Trends in US Outpatient Antibiotic Prescriptions During the Coronavirus Disease 2019 Pandemic. Clin Infect Dis. 2021;73(3): e652-60.
de Lusignan S, Joy M, Sherlock J, Tripathy M, van Hecke O, Gbinigie K, et al. PRINCIPLE trial demonstrates scope for in-pandemic improvement in primary care antibiotic stewardship: a retrospective sentinel network cohort study. BJGP. 2021;5(5):87.
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.
Touret F, Gilles M, Barral K, Nougairède A, van Helden J, Decroly E, de Lamballerie X, Coutard B. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci Rep. 2020;10(1):13093.
Oliver ME, Hinks TSC. Azithromycin in viral infections. Rev Med Virol. 2021;31(2):e2163.
Min JY, Jang YJ. Macrolide therapy in respiratory viral infections. Mediat Inflamm. 2012;2012:649.
Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (principle): A randomised, controlled, open-label, adaptive platform trial. Lancet 2021;397:1063-74.
Recovery Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (Recovery): A randomised, controlled, open-label, platform trial. Lancet 2021;397:605-12.
Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020;383(21):2041-52.
Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396(10256): 959-67.
Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, Gold HS. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(9):1036-41.
Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment. Heart Rhythm. 2020;17(7):e231-2.
Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviv- ing Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020;46:854-87.
Antibiotics. Available at: https://www.ecdc.europa. eu/sites/default/files/documents/surveillance-antimicrobial. Accessed on 20 February 2022.
Covid-19 antibiotics. Available at: https://www.apps. who.int/iris/bitstream/handle/10665/279656/9789241515061-eng.pdf. Accessed on 20 February 2022.
Arcari G, Raponi G, Sacco F, Bibbolino G, Di Lella FM, Alessandri F, et al. Klebsiella pneumoniae infections in COVID-19 patients: a 2-month retro- spective analysis in an Italian hospital. Int J Antimicrob Agents. 2021;57:12-9.
Belvisi V, Del Borgo C, Vita S, Redaelli P, Dolce P, Pacella D, et al. Impact of SARS CoV-2 pandemic on carbapenemase-producing Klebsiella pneumoniae preven- tion and control programme: convergent or divergent action? J Hosp Infect 2021;109:29-31.
Sepulveda J, Westblade LF, Whittier S, Satlin MJ, Greendyke WG, Aaron JG, et al. Bacteremia and Blood Culture Utilization during COVID-19 Surge in New York City. J Clin Microbiol. 2020;58:32-8.
Denny S, Rawson TM, Hart P, Satta G, Abdulaal A, Hughes S, et al. Bacteraemia vari- ation during the COVID-19 pandemic; a multi-centre UK secondary care ecolog- ical analysis. BMC Infect Dis. 2021;21: 556.
Cataldo MA, Tetaj N, Selleri M, Marchioni L, Capone A, Caraffa E, et al. Incidence of bacterial and fungal bloodstream infections in COVID-19 patients in intensive care: An alarming “collateral effect. J Glob Antimicrob Resist. 2020;23:290-1.
Søgaard KK, Baettig V, Osthoff M, Marsch S, Leuzinger K, Schweitzer M, et al. Community-acquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia. J In- tensive Care. 2021;9:10.
Zhang H, Zhang Y, Wu J, Li Y, Zhou X, Li X, et al. Risks and features of secondary infections in severe and critical ill COVID-19 patients. Emerg Microbes Infect. 2020;9:1958-64.
Bassetti M, Righi E, Carnelutti A. Bloodstream infections in the Intensive Care Unit. Virul. 2016;7: 267-79.
Kuster SP, Ruef C, Bollinger AK. Correlation between case mix index and antibiotic use in hospitals. J Antimicrob Chemother 2008;62:837-42.
